Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart Failure | 328 | 2024 | 11670 | 15.430 |
Why?
|
Stroke Volume | 227 | 2024 | 5486 | 9.900 |
Why?
|
Angiotensin Receptor Antagonists | 87 | 2024 | 1040 | 7.640 |
Why?
|
Tetrazoles | 76 | 2024 | 909 | 7.460 |
Why?
|
Biphenyl Compounds | 80 | 2024 | 1007 | 6.170 |
Why?
|
Spironolactone | 37 | 2024 | 409 | 5.760 |
Why?
|
Enalapril | 38 | 2024 | 312 | 4.800 |
Why?
|
Drug Combinations | 72 | 2024 | 2048 | 3.740 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 50 | 2024 | 1517 | 3.530 |
Why?
|
Glucosides | 31 | 2024 | 512 | 3.000 |
Why?
|
Ventricular Function, Left | 69 | 2024 | 3873 | 2.830 |
Why?
|
Benzhydryl Compounds | 38 | 2024 | 915 | 2.830 |
Why?
|
Hyperkalemia | 13 | 2024 | 233 | 2.790 |
Why?
|
Hospitalization | 81 | 2024 | 10708 | 2.410 |
Why?
|
Neprilysin | 21 | 2024 | 478 | 2.300 |
Why?
|
Natriuretic Peptide, Brain | 34 | 2024 | 1723 | 2.220 |
Why?
|
Ventricular Dysfunction, Left | 28 | 2024 | 2118 | 2.220 |
Why?
|
Diuretics | 18 | 2024 | 611 | 2.140 |
Why?
|
Sodium Potassium Chloride Symporter Inhibitors | 7 | 2023 | 152 | 1.840 |
Why?
|
Pulmonary Artery | 12 | 2022 | 1927 | 1.530 |
Why?
|
Peptide Fragments | 28 | 2024 | 5109 | 1.530 |
Why?
|
Antihypertensive Agents | 18 | 2024 | 2018 | 1.410 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 7 | 2023 | 244 | 1.270 |
Why?
|
Anemia | 12 | 2023 | 1504 | 1.240 |
Why?
|
Diabetes Mellitus, Type 2 | 34 | 2024 | 12143 | 1.140 |
Why?
|
Aged | 192 | 2024 | 169092 | 1.130 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 14 | 2020 | 431 | 1.120 |
Why?
|
Humans | 388 | 2024 | 760740 | 1.120 |
Why?
|
Double-Blind Method | 61 | 2024 | 12333 | 1.120 |
Why?
|
Naphthyridines | 5 | 2024 | 143 | 1.080 |
Why?
|
Glomerular Filtration Rate | 18 | 2024 | 2174 | 1.050 |
Why?
|
Heart-Assist Devices | 5 | 2023 | 1288 | 1.010 |
Why?
|
Cardiac Resynchronization Therapy | 5 | 2020 | 557 | 0.980 |
Why?
|
Fumarates | 12 | 2020 | 131 | 0.970 |
Why?
|
Potassium | 7 | 2022 | 1311 | 0.940 |
Why?
|
Middle Aged | 174 | 2024 | 220603 | 0.890 |
Why?
|
Angiotensinogen | 2 | 2024 | 161 | 0.890 |
Why?
|
Hypertension | 15 | 2024 | 8532 | 0.890 |
Why?
|
Male | 221 | 2024 | 360402 | 0.880 |
Why?
|
Hypotension | 8 | 2024 | 879 | 0.880 |
Why?
|
Renal Insufficiency, Chronic | 14 | 2024 | 2252 | 0.860 |
Why?
|
Hypokalemia | 5 | 2019 | 153 | 0.860 |
Why?
|
Prognosis | 66 | 2024 | 29601 | 0.850 |
Why?
|
Amides | 12 | 2020 | 449 | 0.850 |
Why?
|
Female | 219 | 2024 | 392203 | 0.810 |
Why?
|
Patient Readmission | 7 | 2018 | 3269 | 0.800 |
Why?
|
Natriuretic Peptides | 5 | 2023 | 155 | 0.790 |
Why?
|
Disease Management | 7 | 2019 | 2506 | 0.790 |
Why?
|
Cardiac Output, Low | 2 | 2017 | 191 | 0.790 |
Why?
|
Defibrillators, Implantable | 8 | 2021 | 1483 | 0.780 |
Why?
|
Cause of Death | 17 | 2024 | 3683 | 0.780 |
Why?
|
Cardiomyopathies | 9 | 2023 | 1948 | 0.760 |
Why?
|
Kidney Diseases | 7 | 2023 | 2090 | 0.750 |
Why?
|
Treatment Outcome | 88 | 2024 | 64572 | 0.730 |
Why?
|
Guideline Adherence | 3 | 2021 | 2218 | 0.730 |
Why?
|
Palliative Care | 6 | 2024 | 3593 | 0.730 |
Why?
|
Angiotensins | 3 | 2023 | 142 | 0.720 |
Why?
|
Atrial Fibrillation | 14 | 2023 | 5031 | 0.710 |
Why?
|
Heart Failure, Diastolic | 5 | 2023 | 76 | 0.710 |
Why?
|
Cardiovascular Diseases | 30 | 2022 | 15498 | 0.700 |
Why?
|
Death, Sudden, Cardiac | 12 | 2021 | 1551 | 0.680 |
Why?
|
Troponin T | 6 | 2023 | 780 | 0.670 |
Why?
|
Temporal Arteries | 2 | 2017 | 154 | 0.660 |
Why?
|
Cardiac Resynchronization Therapy Devices | 3 | 2020 | 122 | 0.660 |
Why?
|
Edema, Cardiac | 1 | 2018 | 19 | 0.630 |
Why?
|
Kidney | 12 | 2024 | 7044 | 0.620 |
Why?
|
Monitoring, Ambulatory | 3 | 2022 | 355 | 0.610 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2020 | 363 | 0.610 |
Why?
|
Benzimidazoles | 8 | 2020 | 858 | 0.610 |
Why?
|
Aged, 80 and over | 51 | 2024 | 58919 | 0.590 |
Why?
|
Exanthema | 1 | 2022 | 503 | 0.590 |
Why?
|
Renin | 6 | 2016 | 640 | 0.580 |
Why?
|
Hematinics | 7 | 2017 | 282 | 0.570 |
Why?
|
Furosemide | 7 | 2023 | 170 | 0.570 |
Why?
|
Cachexia | 1 | 2019 | 202 | 0.570 |
Why?
|
Prospective Studies | 52 | 2024 | 54364 | 0.560 |
Why?
|
Heart Failure, Systolic | 4 | 2023 | 135 | 0.560 |
Why?
|
Hydrazones | 1 | 2017 | 103 | 0.550 |
Why?
|
Shock, Cardiogenic | 1 | 2022 | 709 | 0.550 |
Why?
|
Randomized Controlled Trials as Topic | 28 | 2024 | 10203 | 0.550 |
Why?
|
Social Work | 1 | 2018 | 158 | 0.550 |
Why?
|
Nutrition Assessment | 2 | 2019 | 726 | 0.540 |
Why?
|
Giant Cell Arteritis | 2 | 2017 | 306 | 0.540 |
Why?
|
Pulmonary Wedge Pressure | 2 | 2020 | 273 | 0.540 |
Why?
|
Quality of Life | 26 | 2024 | 13359 | 0.530 |
Why?
|
Stroke | 13 | 2023 | 9715 | 0.530 |
Why?
|
Hemodynamics | 12 | 2024 | 4160 | 0.520 |
Why?
|
Heart Valve Diseases | 3 | 2023 | 1028 | 0.490 |
Why?
|
Ambulatory Care | 6 | 2019 | 2768 | 0.490 |
Why?
|
Home Care Services | 2 | 2012 | 648 | 0.470 |
Why?
|
Patient Dropouts | 2 | 2016 | 410 | 0.470 |
Why?
|
Renin-Angiotensin System | 4 | 2020 | 737 | 0.470 |
Why?
|
Hyperemia | 1 | 2015 | 221 | 0.470 |
Why?
|
Troponin I | 1 | 2018 | 650 | 0.460 |
Why?
|
Aorta | 2 | 2013 | 2041 | 0.450 |
Why?
|
Patient Care Planning | 2 | 2019 | 905 | 0.440 |
Why?
|
Advance Care Planning | 2 | 2020 | 683 | 0.440 |
Why?
|
Adrenergic beta-Antagonists | 7 | 2024 | 1241 | 0.440 |
Why?
|
Risk Assessment | 22 | 2023 | 23974 | 0.440 |
Why?
|
Electrocardiography, Ambulatory | 1 | 2015 | 574 | 0.420 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2020 | 940 | 0.420 |
Why?
|
Diabetic Nephropathies | 4 | 2015 | 972 | 0.420 |
Why?
|
Blood Pressure | 14 | 2024 | 8473 | 0.420 |
Why?
|
Coronary Stenosis | 2 | 2017 | 794 | 0.410 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3088 | 0.410 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3209 | 0.400 |
Why?
|
Ventricular Remodeling | 4 | 2024 | 1265 | 0.390 |
Why?
|
Vascular Resistance | 2 | 2012 | 930 | 0.390 |
Why?
|
Polypharmacy | 3 | 2024 | 306 | 0.390 |
Why?
|
Follow-Up Studies | 33 | 2024 | 39062 | 0.390 |
Why?
|
Sodium | 5 | 2022 | 1588 | 0.390 |
Why?
|
Practice Guidelines as Topic | 6 | 2020 | 7390 | 0.390 |
Why?
|
Cardiovascular Agents | 6 | 2019 | 840 | 0.380 |
Why?
|
Survival Rate | 24 | 2021 | 12719 | 0.380 |
Why?
|
Diastole | 4 | 2014 | 781 | 0.380 |
Why?
|
Patient Care Team | 2 | 2020 | 2515 | 0.370 |
Why?
|
Triage | 3 | 2018 | 984 | 0.370 |
Why?
|
Surgical Procedures, Operative | 1 | 2022 | 1924 | 0.370 |
Why?
|
Albuminuria | 5 | 2018 | 655 | 0.370 |
Why?
|
Pheochromocytoma | 2 | 2009 | 328 | 0.360 |
Why?
|
Infusions, Intravenous | 5 | 2019 | 2214 | 0.360 |
Why?
|
Telemedicine | 3 | 2020 | 3051 | 0.360 |
Why?
|
Drug-Eluting Stents | 3 | 2017 | 681 | 0.360 |
Why?
|
Coronary Occlusion | 1 | 2013 | 304 | 0.360 |
Why?
|
Prediabetic State | 3 | 2022 | 545 | 0.350 |
Why?
|
Diabetes Mellitus | 9 | 2023 | 5838 | 0.350 |
Why?
|
Hemoglobins | 3 | 2013 | 1524 | 0.350 |
Why?
|
Diabetic Angiopathies | 3 | 2015 | 803 | 0.340 |
Why?
|
Proportional Hazards Models | 15 | 2024 | 12448 | 0.340 |
Why?
|
Electrocardiography | 11 | 2024 | 6346 | 0.340 |
Why?
|
Growth Differentiation Factor 15 | 3 | 2023 | 197 | 0.330 |
Why?
|
Cardiomyopathy, Dilated | 4 | 2023 | 831 | 0.330 |
Why?
|
Cardiology | 4 | 2019 | 1656 | 0.330 |
Why?
|
Glucocorticoids | 3 | 2017 | 2160 | 0.330 |
Why?
|
Patient Admission | 2 | 2018 | 1365 | 0.330 |
Why?
|
Intermittent Claudication | 3 | 2017 | 304 | 0.320 |
Why?
|
Monitoring, Physiologic | 2 | 2021 | 1780 | 0.320 |
Why?
|
Patient Discharge | 4 | 2023 | 3442 | 0.320 |
Why?
|
Comorbidity | 14 | 2023 | 10507 | 0.310 |
Why?
|
Death, Sudden | 2 | 2022 | 301 | 0.310 |
Why?
|
Risk Factors | 44 | 2024 | 74128 | 0.310 |
Why?
|
Influenza Vaccines | 3 | 2022 | 767 | 0.310 |
Why?
|
Microcirculation | 1 | 2013 | 1272 | 0.300 |
Why?
|
Terminal Care | 2 | 2020 | 1755 | 0.290 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 5 | 2023 | 3204 | 0.290 |
Why?
|
Societies, Medical | 3 | 2019 | 3901 | 0.290 |
Why?
|
Pregnancy Complications | 3 | 2010 | 2948 | 0.290 |
Why?
|
Adrenal Gland Neoplasms | 2 | 2009 | 732 | 0.290 |
Why?
|
Kaplan-Meier Estimate | 14 | 2024 | 6473 | 0.280 |
Why?
|
Thrombosis | 2 | 2013 | 2942 | 0.280 |
Why?
|
Heart Arrest | 6 | 2019 | 1513 | 0.280 |
Why?
|
Fibrinolysis | 1 | 2008 | 331 | 0.280 |
Why?
|
Dose-Response Relationship, Drug | 13 | 2021 | 10754 | 0.280 |
Why?
|
Obesity | 8 | 2023 | 12934 | 0.280 |
Why?
|
RNA Interference | 3 | 2024 | 2829 | 0.270 |
Why?
|
Pandemics | 6 | 2023 | 8652 | 0.270 |
Why?
|
Single-Blind Method | 7 | 2019 | 1575 | 0.260 |
Why?
|
Pain | 2 | 2017 | 5062 | 0.250 |
Why?
|
Ambulatory Care Facilities | 3 | 2019 | 934 | 0.250 |
Why?
|
Time Factors | 22 | 2024 | 39908 | 0.250 |
Why?
|
Uric Acid | 3 | 2023 | 806 | 0.240 |
Why?
|
Coronary Disease | 3 | 2018 | 5911 | 0.240 |
Why?
|
Endpoint Determination | 2 | 2018 | 590 | 0.240 |
Why?
|
Directive Counseling | 1 | 2006 | 170 | 0.240 |
Why?
|
Myocardium | 3 | 2013 | 4725 | 0.240 |
Why?
|
Coronary Angiography | 6 | 2018 | 4470 | 0.240 |
Why?
|
Influenza, Human | 3 | 2022 | 1521 | 0.240 |
Why?
|
Disease Progression | 9 | 2024 | 13495 | 0.240 |
Why?
|
American Heart Association | 2 | 2019 | 1039 | 0.230 |
Why?
|
Morbidity | 8 | 2020 | 1750 | 0.230 |
Why?
|
Silicates | 1 | 2024 | 47 | 0.230 |
Why?
|
Algorithms | 6 | 2021 | 14024 | 0.230 |
Why?
|
Cardiomyopathy, Hypertrophic | 2 | 2017 | 1310 | 0.230 |
Why?
|
Kidney Failure, Chronic | 3 | 2016 | 2474 | 0.220 |
Why?
|
Coronary Artery Disease | 6 | 2018 | 6403 | 0.220 |
Why?
|
Chronic Disease | 10 | 2024 | 9310 | 0.220 |
Why?
|
Sleep Apnea Syndromes | 2 | 2012 | 978 | 0.220 |
Why?
|
Dihydropyridines | 1 | 2023 | 67 | 0.220 |
Why?
|
Health Status | 6 | 2023 | 4076 | 0.220 |
Why?
|
Cardiotonic Agents | 3 | 2018 | 539 | 0.220 |
Why?
|
North America | 7 | 2024 | 1273 | 0.220 |
Why?
|
United States | 31 | 2024 | 72292 | 0.220 |
Why?
|
Aortic Diseases | 1 | 2009 | 735 | 0.210 |
Why?
|
Predictive Value of Tests | 12 | 2021 | 15250 | 0.210 |
Why?
|
Erythrocyte Indices | 1 | 2023 | 144 | 0.210 |
Why?
|
Clinical Trials as Topic | 6 | 2024 | 7995 | 0.210 |
Why?
|
Protease Inhibitors | 2 | 2016 | 753 | 0.210 |
Why?
|
Incidence | 12 | 2021 | 21339 | 0.210 |
Why?
|
Malnutrition | 2 | 2019 | 622 | 0.210 |
Why?
|
Telemetry | 2 | 2016 | 199 | 0.210 |
Why?
|
Heart Ventricles | 5 | 2019 | 3796 | 0.200 |
Why?
|
Research Design | 3 | 2023 | 6174 | 0.200 |
Why?
|
Europe | 8 | 2024 | 3415 | 0.200 |
Why?
|
Echocardiography | 10 | 2019 | 4987 | 0.200 |
Why?
|
Sex Factors | 10 | 2024 | 10549 | 0.200 |
Why?
|
Injections, Subcutaneous | 1 | 2023 | 671 | 0.190 |
Why?
|
Hypoglycemic Agents | 6 | 2024 | 3085 | 0.190 |
Why?
|
Aortic Valve | 2 | 2008 | 1955 | 0.190 |
Why?
|
Hypertension, Pulmonary | 1 | 2012 | 1582 | 0.190 |
Why?
|
Systole | 7 | 2020 | 935 | 0.190 |
Why?
|
Renal Insufficiency | 2 | 2018 | 808 | 0.190 |
Why?
|
Fluorodeoxyglucose F18 | 3 | 2019 | 2008 | 0.190 |
Why?
|
Erythropoietin | 3 | 2015 | 719 | 0.180 |
Why?
|
Endothelium, Vascular | 1 | 2013 | 4433 | 0.180 |
Why?
|
Receptors, Angiotensin | 1 | 2021 | 141 | 0.180 |
Why?
|
Myocardial Infarction | 8 | 2024 | 11458 | 0.180 |
Why?
|
Coronary Artery Bypass | 4 | 2021 | 2188 | 0.180 |
Why?
|
Patient Selection | 3 | 2014 | 4237 | 0.180 |
Why?
|
Bundle-Branch Block | 2 | 2020 | 276 | 0.170 |
Why?
|
Metanephrine | 2 | 2009 | 25 | 0.170 |
Why?
|
Sarcoidosis | 2 | 2019 | 520 | 0.170 |
Why?
|
Creatinine | 6 | 2024 | 1895 | 0.170 |
Why?
|
Communication | 2 | 2024 | 3851 | 0.170 |
Why?
|
Heart Valve Prosthesis | 1 | 2008 | 1462 | 0.170 |
Why?
|
Aftercare | 2 | 2023 | 913 | 0.170 |
Why?
|
Drug Therapy, Combination | 10 | 2019 | 6305 | 0.160 |
Why?
|
Angina, Unstable | 1 | 2003 | 888 | 0.160 |
Why?
|
Russia | 5 | 2018 | 382 | 0.160 |
Why?
|
Angiotensin II Type 2 Receptor Blockers | 1 | 2018 | 7 | 0.160 |
Why?
|
Syncope | 3 | 2018 | 428 | 0.160 |
Why?
|
Catecholamines | 2 | 2010 | 387 | 0.160 |
Why?
|
Diet | 2 | 2023 | 8049 | 0.160 |
Why?
|
Heart Transplantation | 3 | 2019 | 3233 | 0.160 |
Why?
|
Retrospective Studies | 19 | 2024 | 80583 | 0.160 |
Why?
|
Positron-Emission Tomography | 4 | 2019 | 6483 | 0.160 |
Why?
|
Cardiovascular Physiological Phenomena | 1 | 2020 | 241 | 0.160 |
Why?
|
Myocardial Ischemia | 2 | 2021 | 2110 | 0.150 |
Why?
|
Peripheral Arterial Disease | 3 | 2023 | 1271 | 0.150 |
Why?
|
Stents | 2 | 2009 | 3177 | 0.150 |
Why?
|
Canrenone | 1 | 2017 | 5 | 0.150 |
Why?
|
Blood Glucose | 6 | 2024 | 6390 | 0.150 |
Why?
|
Funnel Chest | 1 | 2018 | 74 | 0.150 |
Why?
|
Postoperative Period | 1 | 2022 | 1812 | 0.150 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2023 | 3245 | 0.150 |
Why?
|
Electrophysiology | 1 | 2020 | 1262 | 0.150 |
Why?
|
Health Status Disparities | 2 | 2019 | 1846 | 0.140 |
Why?
|
Age Factors | 10 | 2024 | 18381 | 0.140 |
Why?
|
Subclavian Artery | 1 | 2017 | 133 | 0.140 |
Why?
|
Mortality | 4 | 2021 | 2899 | 0.140 |
Why?
|
Blood Pressure Determination | 2 | 2019 | 633 | 0.140 |
Why?
|
Troponin | 3 | 2018 | 502 | 0.140 |
Why?
|
Georgia (Republic) | 4 | 2018 | 38 | 0.140 |
Why?
|
Pulmonary Edema | 2 | 2009 | 407 | 0.140 |
Why?
|
Tachycardia, Ventricular | 3 | 2023 | 1261 | 0.140 |
Why?
|
Electrodes, Implanted | 1 | 2021 | 838 | 0.140 |
Why?
|
Dyspnea | 5 | 2023 | 1347 | 0.140 |
Why?
|
Prostheses and Implants | 2 | 2024 | 1269 | 0.140 |
Why?
|
Activities of Daily Living | 3 | 2023 | 2419 | 0.130 |
Why?
|
Pacemaker, Artificial | 2 | 2019 | 805 | 0.130 |
Why?
|
Laboratories | 1 | 2020 | 458 | 0.130 |
Why?
|
Methylprednisolone | 1 | 2017 | 385 | 0.130 |
Why?
|
Hypertrophy, Left Ventricular | 5 | 2017 | 851 | 0.130 |
Why?
|
Severity of Illness Index | 8 | 2021 | 15829 | 0.130 |
Why?
|
Micronutrients | 1 | 2019 | 381 | 0.130 |
Why?
|
Hospitals, Community | 1 | 2018 | 365 | 0.130 |
Why?
|
Leg | 2 | 2017 | 1087 | 0.130 |
Why?
|
Gout | 1 | 2023 | 621 | 0.130 |
Why?
|
Thyroid Diseases | 1 | 2019 | 386 | 0.130 |
Why?
|
Respiratory Rate | 1 | 2017 | 175 | 0.130 |
Why?
|
Anti-Obesity Agents | 1 | 2019 | 227 | 0.130 |
Why?
|
Heart Diseases | 1 | 2008 | 2778 | 0.130 |
Why?
|
Pyridazines | 1 | 2017 | 201 | 0.130 |
Why?
|
Cardiac Pacing, Artificial | 1 | 2019 | 852 | 0.120 |
Why?
|
Cardiac Volume | 1 | 2015 | 196 | 0.120 |
Why?
|
Prednisone | 2 | 2017 | 1562 | 0.120 |
Why?
|
Quality of Health Care | 3 | 2023 | 4325 | 0.120 |
Why?
|
Echocardiography, Doppler | 3 | 2014 | 893 | 0.120 |
Why?
|
Dementia | 2 | 2020 | 2686 | 0.120 |
Why?
|
Device Removal | 1 | 2020 | 629 | 0.120 |
Why?
|
Transcutaneous Electric Nerve Stimulation | 1 | 2017 | 170 | 0.120 |
Why?
|
Decision Trees | 1 | 2016 | 504 | 0.120 |
Why?
|
Chi-Square Distribution | 3 | 2016 | 3410 | 0.120 |
Why?
|
Lung | 2 | 2012 | 9999 | 0.120 |
Why?
|
Insulin | 3 | 2018 | 6593 | 0.120 |
Why?
|
Multivariate Analysis | 6 | 2020 | 12043 | 0.110 |
Why?
|
Sarcopenia | 1 | 2019 | 370 | 0.110 |
Why?
|
Emergency Service, Hospital | 2 | 2013 | 7873 | 0.110 |
Why?
|
Kansas | 2 | 2023 | 37 | 0.110 |
Why?
|
Dietary Proteins | 1 | 2019 | 951 | 0.110 |
Why?
|
Decision Support Systems, Clinical | 1 | 2023 | 1171 | 0.110 |
Why?
|
Pharmacists | 1 | 2016 | 259 | 0.110 |
Why?
|
Internationality | 2 | 2019 | 1000 | 0.110 |
Why?
|
Carotid Arteries | 1 | 2017 | 941 | 0.110 |
Why?
|
Hospital Mortality | 4 | 2020 | 5292 | 0.110 |
Why?
|
Professional Role | 1 | 2016 | 313 | 0.110 |
Why?
|
Intermittent Positive-Pressure Ventilation | 1 | 2012 | 15 | 0.110 |
Why?
|
Frail Elderly | 1 | 2018 | 765 | 0.110 |
Why?
|
Adult | 25 | 2024 | 220995 | 0.110 |
Why?
|
Aldosterone | 2 | 2022 | 869 | 0.100 |
Why?
|
Electrophysiologic Techniques, Cardiac | 1 | 2015 | 480 | 0.100 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2013 | 411 | 0.100 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2018 | 628 | 0.100 |
Why?
|
Ultrasonography, Interventional | 2 | 2017 | 1496 | 0.100 |
Why?
|
Prevalence | 7 | 2024 | 15702 | 0.100 |
Why?
|
Electric Countershock | 1 | 2015 | 532 | 0.100 |
Why?
|
Hemofiltration | 1 | 2012 | 59 | 0.100 |
Why?
|
Arrhythmias, Cardiac | 3 | 2022 | 2234 | 0.100 |
Why?
|
Cardiovascular System | 1 | 2020 | 834 | 0.100 |
Why?
|
Pulmonary Medicine | 1 | 2014 | 221 | 0.100 |
Why?
|
Case-Control Studies | 6 | 2020 | 22153 | 0.100 |
Why?
|
Influenza A virus | 1 | 2015 | 458 | 0.100 |
Why?
|
Diet, Mediterranean | 1 | 2019 | 738 | 0.100 |
Why?
|
Cystatin C | 2 | 2023 | 270 | 0.100 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 2 | 2023 | 151 | 0.100 |
Why?
|
Social Behavior | 1 | 2018 | 1135 | 0.100 |
Why?
|
Sweden | 3 | 2020 | 1379 | 0.100 |
Why?
|
Coronary Vessels | 2 | 2018 | 3095 | 0.090 |
Why?
|
Fetal Death | 2 | 2009 | 435 | 0.090 |
Why?
|
Counseling | 1 | 2019 | 1538 | 0.090 |
Why?
|
Body Weight | 1 | 2021 | 4615 | 0.090 |
Why?
|
Diabetes Complications | 2 | 2020 | 1315 | 0.090 |
Why?
|
Athletes | 1 | 2018 | 1137 | 0.090 |
Why?
|
Patient Preference | 1 | 2018 | 925 | 0.090 |
Why?
|
Proteomics | 1 | 2024 | 3836 | 0.090 |
Why?
|
Hospitals | 2 | 2021 | 3879 | 0.090 |
Why?
|
Research | 1 | 2019 | 1977 | 0.090 |
Why?
|
Biopsy | 3 | 2017 | 6763 | 0.090 |
Why?
|
Latin America | 2 | 2024 | 407 | 0.090 |
Why?
|
Pregnancy Trimester, Third | 2 | 2009 | 582 | 0.090 |
Why?
|
Diabetic Cardiomyopathies | 1 | 2011 | 90 | 0.090 |
Why?
|
Angioplasty, Balloon, Coronary | 3 | 2012 | 1723 | 0.090 |
Why?
|
New York | 2 | 2023 | 875 | 0.090 |
Why?
|
Income | 1 | 2019 | 1870 | 0.090 |
Why?
|
Cognition | 2 | 2024 | 6988 | 0.090 |
Why?
|
Statistics as Topic | 2 | 2015 | 2358 | 0.080 |
Why?
|
Logistic Models | 3 | 2020 | 13248 | 0.080 |
Why?
|
Tunica Intima | 1 | 2011 | 458 | 0.080 |
Why?
|
Pneumonia | 1 | 2021 | 2143 | 0.080 |
Why?
|
Catheter Ablation | 2 | 2015 | 2634 | 0.080 |
Why?
|
Case Management | 1 | 2011 | 272 | 0.080 |
Why?
|
Bariatric Surgery | 1 | 2019 | 992 | 0.080 |
Why?
|
Heart Rate | 4 | 2023 | 4181 | 0.080 |
Why?
|
Thrombectomy | 1 | 2013 | 702 | 0.080 |
Why?
|
Data Collection | 1 | 2018 | 3316 | 0.080 |
Why?
|
Vaccination | 2 | 2022 | 3370 | 0.080 |
Why?
|
Ascorbic Acid | 1 | 2011 | 655 | 0.080 |
Why?
|
Cohort Studies | 7 | 2020 | 41464 | 0.080 |
Why?
|
Patients | 1 | 2014 | 906 | 0.070 |
Why?
|
Administration, Oral | 1 | 2016 | 4010 | 0.070 |
Why?
|
Outpatients | 3 | 2023 | 1596 | 0.070 |
Why?
|
Metformin | 1 | 2016 | 906 | 0.070 |
Why?
|
Academic Medical Centers | 1 | 2018 | 2756 | 0.070 |
Why?
|
Treatment Failure | 4 | 2016 | 2635 | 0.070 |
Why?
|
Remission, Spontaneous | 1 | 2008 | 384 | 0.070 |
Why?
|
Pilot Projects | 2 | 2018 | 8619 | 0.070 |
Why?
|
Equipment Design | 1 | 2015 | 3501 | 0.070 |
Why?
|
Echocardiography, Transesophageal | 1 | 2013 | 1085 | 0.070 |
Why?
|
Weight Loss | 1 | 2019 | 2682 | 0.070 |
Why?
|
Tachycardia | 1 | 2009 | 597 | 0.070 |
Why?
|
Physical Examination | 3 | 2019 | 1254 | 0.070 |
Why?
|
Population Surveillance | 1 | 2017 | 2597 | 0.070 |
Why?
|
Azetidines | 1 | 2008 | 142 | 0.070 |
Why?
|
Vitamin E | 1 | 2011 | 872 | 0.070 |
Why?
|
Survival Analysis | 5 | 2021 | 10072 | 0.070 |
Why?
|
Body Mass Index | 3 | 2022 | 12942 | 0.070 |
Why?
|
Longitudinal Studies | 2 | 2021 | 14599 | 0.070 |
Why?
|
Puerperal Disorders | 1 | 2009 | 300 | 0.070 |
Why?
|
Up-Regulation | 1 | 2016 | 4117 | 0.070 |
Why?
|
Renal Dialysis | 1 | 2016 | 1795 | 0.070 |
Why?
|
Heart Defects, Congenital | 1 | 2023 | 4671 | 0.070 |
Why?
|
Radiopharmaceuticals | 2 | 2019 | 2650 | 0.070 |
Why?
|
Ventricular Outflow Obstruction | 1 | 2008 | 261 | 0.070 |
Why?
|
Extracellular Matrix | 1 | 2013 | 1718 | 0.060 |
Why?
|
Sleep | 1 | 2021 | 4764 | 0.060 |
Why?
|
Simvastatin | 1 | 2008 | 346 | 0.060 |
Why?
|
Urinalysis | 2 | 2018 | 368 | 0.060 |
Why?
|
Surgical Instruments | 1 | 2008 | 383 | 0.060 |
Why?
|
Boston | 2 | 2016 | 9313 | 0.060 |
Why?
|
Medication Adherence | 1 | 2017 | 2175 | 0.060 |
Why?
|
South America | 2 | 2016 | 179 | 0.060 |
Why?
|
Circadian Rhythm | 1 | 2017 | 2569 | 0.060 |
Why?
|
Anticoagulants | 3 | 2023 | 4785 | 0.060 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7805 | 0.060 |
Why?
|
Propanolamines | 1 | 2005 | 163 | 0.060 |
Why?
|
Vasodilator Agents | 2 | 2022 | 973 | 0.060 |
Why?
|
ROC Curve | 1 | 2012 | 3575 | 0.060 |
Why?
|
Sodium-Glucose Transport Proteins | 1 | 2024 | 13 | 0.060 |
Why?
|
Curriculum | 2 | 2015 | 3739 | 0.060 |
Why?
|
Receptors, Cell Surface | 1 | 2013 | 2802 | 0.060 |
Why?
|
Multicenter Studies as Topic | 2 | 2019 | 1700 | 0.060 |
Why?
|
Fluoroscopy | 1 | 2008 | 945 | 0.060 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2018 | 3415 | 0.060 |
Why?
|
Blood Urea Nitrogen | 1 | 2024 | 185 | 0.060 |
Why?
|
Drug Administration Schedule | 3 | 2021 | 4845 | 0.060 |
Why?
|
Argentina | 2 | 2016 | 244 | 0.060 |
Why?
|
Carbazoles | 1 | 2005 | 220 | 0.060 |
Why?
|
Atmosphere | 1 | 2023 | 32 | 0.050 |
Why?
|
Drug Substitution | 2 | 2016 | 290 | 0.050 |
Why?
|
Pre-Eclampsia | 2 | 2009 | 1230 | 0.050 |
Why?
|
Hypovolemia | 1 | 2023 | 48 | 0.050 |
Why?
|
Education, Medical, Graduate | 1 | 2015 | 2373 | 0.050 |
Why?
|
Vascular Diseases | 1 | 2011 | 1159 | 0.050 |
Why?
|
Aptamers, Nucleotide | 1 | 2024 | 164 | 0.050 |
Why?
|
Postpartum Period | 1 | 2009 | 1178 | 0.050 |
Why?
|
Calcium | 1 | 2016 | 5717 | 0.050 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2012 | 1187 | 0.050 |
Why?
|
Diagnostic Errors | 1 | 2009 | 1265 | 0.050 |
Why?
|
Cardiac Surgical Procedures | 1 | 2017 | 3621 | 0.050 |
Why?
|
Beds | 1 | 2021 | 47 | 0.050 |
Why?
|
Critical Care | 1 | 2014 | 2691 | 0.050 |
Why?
|
Atherosclerosis | 1 | 2017 | 3400 | 0.050 |
Why?
|
Headache | 1 | 2009 | 1255 | 0.050 |
Why?
|
Colchicine | 1 | 2023 | 259 | 0.050 |
Why?
|
Exercise | 1 | 2018 | 5886 | 0.050 |
Why?
|
Asymptomatic Diseases | 1 | 2024 | 587 | 0.050 |
Why?
|
Fatigue | 2 | 2020 | 1550 | 0.050 |
Why?
|
Probability | 2 | 2021 | 2475 | 0.050 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2023 | 459 | 0.050 |
Why?
|
Canada | 2 | 2017 | 2120 | 0.050 |
Why?
|
Amyloidosis | 1 | 2008 | 815 | 0.050 |
Why?
|
Animals | 3 | 2020 | 168202 | 0.050 |
Why?
|
Cost-Benefit Analysis | 2 | 2024 | 5493 | 0.040 |
Why?
|
Glucose | 2 | 2022 | 4345 | 0.040 |
Why?
|
Remote Sensing Technology | 1 | 2021 | 92 | 0.040 |
Why?
|
Vaccines, Inactivated | 1 | 2021 | 178 | 0.040 |
Why?
|
Ventricular Fibrillation | 1 | 2023 | 534 | 0.040 |
Why?
|
Calcium Channel Blockers | 1 | 2023 | 694 | 0.040 |
Why?
|
Inpatients | 2 | 2023 | 2545 | 0.040 |
Why?
|
Warfarin | 1 | 2008 | 1477 | 0.040 |
Why?
|
Pregnancy | 3 | 2010 | 29869 | 0.040 |
Why?
|
Patient Education as Topic | 1 | 2009 | 2315 | 0.040 |
Why?
|
Asia, Western | 1 | 2018 | 19 | 0.040 |
Why?
|
C-Reactive Protein | 2 | 2024 | 3820 | 0.040 |
Why?
|
Cholesterol, LDL | 2 | 2021 | 2378 | 0.040 |
Why?
|
Ultrasonography | 1 | 2012 | 5965 | 0.040 |
Why?
|
Self Efficacy | 1 | 2023 | 636 | 0.040 |
Why?
|
Liver Cirrhosis | 1 | 2009 | 1927 | 0.040 |
Why?
|
Europe, Eastern | 1 | 2018 | 72 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2019 | 36401 | 0.040 |
Why?
|
Registries | 3 | 2020 | 8209 | 0.040 |
Why?
|
Asia, Southeastern | 1 | 2018 | 114 | 0.040 |
Why?
|
Quebec | 1 | 2018 | 140 | 0.040 |
Why?
|
Americas | 1 | 2018 | 110 | 0.040 |
Why?
|
Cost of Illness | 2 | 2020 | 1937 | 0.040 |
Why?
|
Mitral Valve Insufficiency | 1 | 2008 | 1400 | 0.040 |
Why?
|
Recurrence | 3 | 2018 | 8426 | 0.040 |
Why?
|
Biological Availability | 1 | 2019 | 389 | 0.040 |
Why?
|
Medication Therapy Management | 1 | 2019 | 130 | 0.040 |
Why?
|
Angioedema | 1 | 2019 | 184 | 0.040 |
Why?
|
Medicare | 3 | 2024 | 6774 | 0.040 |
Why?
|
Digoxin | 1 | 2018 | 246 | 0.040 |
Why?
|
Nausea | 1 | 2020 | 679 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 2010 | 12966 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2021 | 857 | 0.040 |
Why?
|
Asia | 1 | 2018 | 616 | 0.040 |
Why?
|
Cheyne-Stokes Respiration | 1 | 2017 | 38 | 0.030 |
Why?
|
Japan | 1 | 2021 | 1372 | 0.030 |
Why?
|
Transducers, Pressure | 1 | 2016 | 51 | 0.030 |
Why?
|
Protein Precursors | 1 | 2020 | 1131 | 0.030 |
Why?
|
Recovery of Function | 2 | 2017 | 2977 | 0.030 |
Why?
|
Placebos | 1 | 2020 | 1667 | 0.030 |
Why?
|
Muscle, Skeletal | 1 | 2010 | 4947 | 0.030 |
Why?
|
Young Adult | 4 | 2017 | 59191 | 0.030 |
Why?
|
Wireless Technology | 1 | 2016 | 97 | 0.030 |
Why?
|
Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2016 | 128 | 0.030 |
Why?
|
Credentialing | 1 | 2015 | 115 | 0.030 |
Why?
|
Heart Conduction System | 1 | 2020 | 992 | 0.030 |
Why?
|
Polysomnography | 1 | 2021 | 1852 | 0.030 |
Why?
|
Drug Prescriptions | 1 | 2023 | 1669 | 0.030 |
Why?
|
Sarcomeres | 1 | 2017 | 369 | 0.030 |
Why?
|
RNA | 1 | 2024 | 2713 | 0.030 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2014 | 167 | 0.030 |
Why?
|
Needs Assessment | 1 | 2019 | 1139 | 0.030 |
Why?
|
USSR | 1 | 2012 | 18 | 0.030 |
Why?
|
Linear Models | 2 | 2016 | 5866 | 0.030 |
Why?
|
Length of Stay | 2 | 2020 | 6418 | 0.030 |
Why?
|
Age Distribution | 1 | 2018 | 2872 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2019 | 960 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2019 | 1110 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2023 | 5239 | 0.030 |
Why?
|
Withholding Treatment | 1 | 2017 | 615 | 0.030 |
Why?
|
Carbon Dioxide | 1 | 2017 | 1148 | 0.030 |
Why?
|
Cholesterol | 1 | 2021 | 2902 | 0.030 |
Why?
|
Australia | 1 | 2016 | 1249 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2022 | 2637 | 0.020 |
Why?
|
Brazil | 1 | 2016 | 1229 | 0.020 |
Why?
|
Diffusion of Innovation | 1 | 2017 | 729 | 0.020 |
Why?
|
Neoplasms | 1 | 2020 | 22131 | 0.020 |
Why?
|
Propensity Score | 1 | 2019 | 1912 | 0.020 |
Why?
|
Drug Interactions | 1 | 2016 | 1415 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2020 | 20077 | 0.020 |
Why?
|
Netherlands | 1 | 2016 | 2222 | 0.020 |
Why?
|
Placebo Effect | 1 | 2015 | 518 | 0.020 |
Why?
|
Dependovirus | 1 | 2016 | 712 | 0.020 |
Why?
|
Decision Making | 1 | 2024 | 3919 | 0.020 |
Why?
|
Medical Oncology | 1 | 2022 | 2317 | 0.020 |
Why?
|
Intention to Treat Analysis | 1 | 2011 | 413 | 0.020 |
Why?
|
Glucose Clamp Technique | 1 | 2010 | 262 | 0.020 |
Why?
|
Health Care Costs | 1 | 2003 | 3238 | 0.020 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2018 | 992 | 0.020 |
Why?
|
Losartan | 1 | 2011 | 263 | 0.020 |
Why?
|
United States Food and Drug Administration | 1 | 2018 | 1661 | 0.020 |
Why?
|
Adrenergic alpha-Antagonists | 1 | 2009 | 174 | 0.020 |
Why?
|
Amlodipine | 1 | 2009 | 84 | 0.020 |
Why?
|
Kidney Function Tests | 1 | 2011 | 677 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 2015 | 1810 | 0.020 |
Why?
|
Hypoglycemia | 1 | 2016 | 883 | 0.020 |
Why?
|
Amiodarone | 1 | 2010 | 217 | 0.020 |
Why?
|
Odds Ratio | 1 | 2020 | 9644 | 0.020 |
Why?
|
Regression Analysis | 1 | 2018 | 6339 | 0.020 |
Why?
|
Bumetanide | 1 | 2008 | 98 | 0.020 |
Why?
|
New England | 1 | 2011 | 1050 | 0.020 |
Why?
|
Radial Artery | 1 | 2009 | 187 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2020 | 3599 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2019 | 3680 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8516 | 0.020 |
Why?
|
Stem Cell Transplantation | 1 | 2016 | 1600 | 0.020 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2018 | 1553 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2018 | 3705 | 0.020 |
Why?
|
Depression | 2 | 2020 | 8132 | 0.020 |
Why?
|
Triglycerides | 1 | 2015 | 2459 | 0.020 |
Why?
|
Risk | 1 | 2019 | 9603 | 0.020 |
Why?
|
Manometry | 1 | 2009 | 453 | 0.020 |
Why?
|
Acute Disease | 1 | 2017 | 7236 | 0.020 |
Why?
|
Thromboembolism | 1 | 2013 | 991 | 0.020 |
Why?
|
Demography | 1 | 2011 | 1643 | 0.020 |
Why?
|
Shock, Septic | 1 | 2013 | 769 | 0.020 |
Why?
|
Developing Countries | 1 | 2019 | 2868 | 0.020 |
Why?
|
Organ Size | 1 | 2011 | 2252 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2016 | 3392 | 0.020 |
Why?
|
Biological Transport | 1 | 2010 | 2089 | 0.020 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2010 | 763 | 0.020 |
Why?
|
Electronic Health Records | 1 | 2023 | 4810 | 0.020 |
Why?
|
Models, Statistical | 1 | 2020 | 5074 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2016 | 6807 | 0.020 |
Why?
|
Heart | 1 | 2018 | 4403 | 0.010 |
Why?
|
Creatine Kinase, MB Form | 1 | 2004 | 202 | 0.010 |
Why?
|
Smoking | 1 | 2021 | 9054 | 0.010 |
Why?
|
Inflammation | 1 | 2024 | 10759 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2009 | 2851 | 0.010 |
Why?
|
Survivors | 1 | 2014 | 2373 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2019 | 14649 | 0.010 |
Why?
|
Health Care Surveys | 1 | 2011 | 2422 | 0.010 |
Why?
|
Adolescent | 3 | 2017 | 88247 | 0.010 |
Why?
|
Kinetics | 1 | 2010 | 6370 | 0.010 |
Why?
|
Health Status Indicators | 1 | 2008 | 970 | 0.010 |
Why?
|
Creatine Kinase | 1 | 2004 | 685 | 0.010 |
Why?
|
Life Expectancy | 1 | 2009 | 1242 | 0.010 |
Why?
|
Lower Extremity | 1 | 2010 | 1200 | 0.010 |
Why?
|
Myocarditis | 1 | 2010 | 788 | 0.010 |
Why?
|
Genotype | 1 | 2017 | 12977 | 0.010 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2014 | 2746 | 0.010 |
Why?
|
Life Style | 1 | 2012 | 3907 | 0.010 |
Why?
|
Isoenzymes | 1 | 2004 | 1687 | 0.010 |
Why?
|
Clinical Competence | 1 | 2015 | 4790 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2020 | 26065 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2011 | 4172 | 0.010 |
Why?
|
Radiography | 1 | 2009 | 6961 | 0.010 |
Why?
|
Sulfonamides | 1 | 2008 | 1977 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2009 | 3451 | 0.010 |
Why?
|
Insulin Resistance | 1 | 2010 | 3954 | 0.010 |
Why?
|
Mutation | 1 | 2017 | 30015 | 0.010 |
Why?
|
Child | 1 | 2017 | 80089 | 0.000 |
Why?
|